Literature DB >> 7699045

Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.

M G Cormican1, R N Jones.   

Abstract

A test battery of bacterial strains with a high incidence of resistance to fluoroquinolones was studied to determine the extent to which susceptibility to levofloxacin could be predicted from susceptibility tests performed with ciprofloxacin or ofloxacin as reagents. Isolates susceptible or intermediately susceptible to ofloxacin (MICs < or = 4 micrograms/ml) may be regarded as susceptible to levofloxacin, with the exception of Enterococcus faecium. Ciprofloxacin-susceptible isolates (MICs < or = 1 micrograms/ml) were also completely susceptible to levofloxacin. Clinical laboratories could use either of the currently used fluoroquinolones (ciprofloxacin or ofloxacin) to predict levofloxacin activity and spectrum with little risk of false-susceptible errors (0.0 to 1.3%). Results obtained with ofloxacin are superior in maximizing recognition of levofloxacin-susceptible clinical isolates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7699045      PMCID: PMC227912          DOI: 10.1128/jcm.33.1.215-216.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  In vitro activity of DR-3355, an optically active ofloxacin.

Authors:  T Une; T Fujimoto; K Sato; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

2.  Inhibition of DNA gyrase by optically active ofloxacin.

Authors:  M Imamura; S Shibamura; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

3.  In vitro activity of S-ofloxacin.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests.

Authors:  M A Pfaller; A L Barry; P C Fuchs
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

5.  Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide.

Authors:  M Tanaka; T Kurata; C Fujisawa; Y Ohshima; H Aoki; O Okazaki; H Hakusui
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

6.  Synthesis and antibacterial activities of optically active ofloxacin.

Authors:  I Hayakawa; S Atarashi; S Yokohama; M Imamura; K Sakano; M Furukawa
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

7.  Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells.

Authors:  A Pascual; I Garcia; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

8.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

9.  Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice.

Authors:  K Akahane; M Kato; S Takayama
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

  9 in total
  2 in total

1.  In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.

Authors:  K P Klugman; T Capper; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

2.  Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.